Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001, 69: 89-95
Boogard HJ, Abe K, Noordegraaf AV, Voelkel NF. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest. 2009a, 135: 794-804
Bogaard HJ, Natarajan H, Henderson SC, Long CC, Kraskauskas D, Smithson L, Ockaili R, McCord JM, Voelkel NF. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation. 2009b, 120: 1951-1960
Boomsma F, van den Meiracker AH. Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use. Cardiovasc Res. 2001, 51: 442-449
Braun MU, Szalai P, Strasser RH, Borst MM. Right ventricular hypertrophy and apoptosis after pulmonary artery banding: regulation of PKC isozymes. Cardiovasc Res. 2003, 59: 658-667
Brown L, Miller J, Dagger A, Sernia C. Cardiac and vascular response after monocrotaline–induced hypertrophy in rats. J Cardiovasc Pharm. 1998, 31: 108-115
Buttrick PM, Kaplan M, Leinwand LA, Scheuer J. Alterations in gene expression in the rat heart after chronic pathological and physiological load. J Mol Cell Cardiol. 1994, 26: 61-67
Carstens LA, Allen JR. Arterial degeneration and glomerular hyalinization in the kidney of monocrotaline-intoxicated rats. Am J Pathol. 1970, 60: 75-92
Champion HC, Michelakis ED, Hassoun PM. Comprehensive invasive and noninvasive approach to the right ventricle pulmonary circulation unit: state of the art and clinical and research implications. Circulation. 2009, 120:
992-1007
Chien KR, Zhu H, Knowlton KU, Miller-Hance W, van-Bilsen M, O`Brien TX, Evans SM. Transcriptional regulation during cardiac growth and development. Ann Rev Physiol. 1993, 55: 77-95
Chin KM, Kim NHS, Rubin LJ. The right ventricle in pulmonary hypertension. Coron Art Dis. 2005, 16: 13-18 Choi DE, Jeong JY, Lim BJ, Chung S, Chang YK, Lee SJ, Na KR, Kim SY, Shin YT, Lee KW. Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats. Am J Physiol - Renal Physiol. 2009, 297: F362-F370 Clozel M, Hess P, Rey M, Iglarz M, Binkert C, Qiu C. Bosentan, Sildenafil and their combination in the monocrotaline model of pulmonary hypertension in rats. Exp Biol Med. 2006, 231: 967-973
Correia-Pinto J, Henriques-Coelho T, Roncon-Albuquerque R, Lourenço AP, Melo-Rocha G, Vasques-Nóvoa F, Gillebert TC, Leite-Moreira A. Time course and mechanisms of left ventricular systolic and diastolic dysfunction in monocrotaline-induced pulmonary hypertension. Bas Res Cardiol. 2009, 104: 535-545
Crabtree GR, Olson EN. NFAT signaling: choreographing the social lives of cells. Cell. 2002, 109: S67-S79 Crabtree GR. Generic signals and specific outcomes: signaling through Ca2+, Calcineurin, and NF-AT. Cell. 1999, 96: 611-614
Daicho T, Yagi T, Marunouchi T, Ohara M, Takeo S, Tanonaka K. Alterations in pharmacological action of the right ventricle of monocrotaline-induced pulmonary hypertensive rats. Biol Pharmacol Bull. 2009, 32: 1378-1384
deFilippi CR, Seliger SL, Maynard S, Christenson RH. Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality. Clin Chem. 2007, 53: 1511-1519
Denhardt DT, Noda M, O`Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001, 107: 1055-1061 Dietrich A,Mederos y Schnitzler M, Gollasch M, Gross V, Storch U, Dubrovska G, Obst M, Yildirim E, Salanova B, Kalwa H, Essin K, Pinkenburg O, Luft FC, Gudermann T, Birnbaumer L. Increased vascular smooth muscle contractility in TRPC6-/- mice. Mol Cell Biol. 2005, 25: 6980-6989
Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K, Schmidt H, Stasch JP, Gnoth MJ, Seeger W, Grimminger F, Schermuly RT. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation. 2006, 113: 286-295
Faber MJ, Dalinghaus M, Lankhuizen IM, Steendijk P, Hop WC, Schoemaker RG, Duncker DJ, Lamers JMJ, Helbing WA. Right and left ventricular function after chronic pulmonary artery banding in rats assessed with biventricular pressure-volume loops. Am J Physiol – Heart Circ Physiol. 2006, 291: H1580-H1586
Faber MJ, Dalinghaus M, Lankhuizen IM, Bezstarosti K, Verhoeven AJM, Duncker DJ, Helbing WA, Lamers JMJ.
Time dependent changes in cytoplasmic proteins of the right ventricle during prolonged pressure overload. J Mol Cell Cardiol. 2007, 43: 197-209
Fabiato A. Calcium-induced release from the sarcoplasmic reticulum. Am J Physiol. 1983, 245: C1-C4
Fisher MR, Forfia PR, Chamera E, Housten-Harris T, Champion HC, Girgis RE, Corretti MC, Hassoun PM.
Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009, 179: 615–621
Frisdal E, Gest V, Viellard-Baron A, Levame M, Lepetit H, Eddahibi S, Lafuma C, Harf A, Adnot S, d’Ortho MP.
Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension. Eur Respir J. 2001, 18:
838-845
Frey R, Mück W, Unger S, Artmeier-Brandt U, Weimann G, Wensing G. Single-dose pharmacokinetics, pharmacodynamics, tolerability and safety of the soluble guanlylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. J Clin Pharmacol. 2008, 48: 926-934
Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G. Sildenafil citrate therapy for pulmonary hypertension. N Engl J Med.
2005, 353: 2148-2157
Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G.
Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2009, 30: 2493-2537
Ghodsi F, Will JA. Changes in pulmonary structure and function induced by monocrotaline intoxication. Am J Physiol. 1981, 240: H149-H155
Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D.
Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002, 360: 895-900
Ghofrani HA, Weimann G, Frey R, Voswinckel R, Thamm M, Bölkow D, Weissmann N, Mück W, Unger S, Wensing G, Schermuly RT, Grimminger F. BAY 63-2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile, improves cardiopulmonary haemodynamics and has therapeutic potential in pulmonary hypertension. BMC Pharmacology. 2007, 7: S8
Ghofrani HA, Grimminger F. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. Eur Respir Rev. 2009, 18: 35-41
Ghofrani HA, Grimminger F. Modulating cGMP to treat lung diseases. Handb Exp Pharmacol. 2009, 191: 469-483 Gonzáles A, López B, Ravassa S, Beaumont J, Arias T, Hermida N, Zudaire A, Díez J. Biochemical markers of myocardial remodeling in hypertensive heart disease. Cardiovasc Res. 2009, 81: 509-518
Graf K, Do YS, Ashizawa N, Meehan WP, Giachelli CM, Marboe CC, Fleck E, Hsueh WA. Myocardial osteopontin expression is associated with left ventricular hypertrophy. Circulation. 1997, 96: 3063-3071
Haddad F, Doyle R, Murphy DJ, Hunt SA. Right ventricular function in cardiovascular disease, part II:
pathophysiology, clinical importance, and management of right ventricular failure. Circulation. 2008, 117: 1717-1731
Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002, 62: 237-244
Hanumegowda UM, Copple BL, Shibuya M, Malle E, Ganey PE, Roth RA. Basement membrane and matrix metalloproteinases in monocrotaline-induced liver injury. Toxicol Sci. 2003, 76: 237-246
Hanson KA, Ziegler JW, Rybalkin SD, Miller JW, Abman SH, Clarke WR. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Am J Physiol - Lung Cell Mol Physiol. 1998, 275: 931-941 Hardziyenka M, Campian ME, de Bruin-Bon R, Michel MC, Tan HL. Sequence of echocardiographic changes during development of right ventricular failure in rat. J Am Soc Echocardiography. 2006, 19: 1272-1279
Hartley CJ, Redy AK, Madala S, Michael LH, Entman ML, Taffet GE. Doppler estimation of reduced coronary flow reserve in mice with pressure overload cardiac hypertrophy. Ultrasound Med Biol. 2008, 34: 892-901
Hasegawa K, Fujiwara H, Itoh H, Nakao K, Fujiwara T, Imura H, Kawai C. Light and electron microscopic localization of brain natriuretic peptide in porcine atrium. Circulation. 1991, 84: 1203-1209
Hasenfuss G, Meyer M, Schillinger W, Preuss M, Pieske B, Just H. Calcium handling proteins in the failing human heart. Bas Res Cardiol. 1997, 92: 87-93
Hébert TE. Signalling in cardiac disease: the molecular deficit at the heart of the problem. Cardiovasc Res. 2001, 50: 7-9
Hessel MHM, Steendijk P, den Adel B, Schutte CI, van der Laarse A. Characterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat. Am J Physiol – Heart Circ Physiol. 2006, 291: H2424-H2430
Hill NS; Warburton RR, Pietras L, Klinger JR. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. J Appl Physiol. 1997, 83: 1209-1215
Hofmann F, Bernhard D, Ludowski R, Weinmeister P. cGMP regulated protein kinases (cGK). Handb Exp Pharmacol. 2009, 191: 137-162
Huber LC, Fischler M, Distler O, Gay S, Speich R, Ulrich S. Pulmonal-arterielle Hypertonie - Aktuelle Therapieansätze. Arzneimitteltherapie. 2007, 25: 364-373
Hudkins KL, Le QC, Segerer S, Johnson RJ, Davis CL, Giachelli CM, Alpers CE. Osteopontin expression in human cyclosporine toxicity. Kidney Int. 2001, 60: 635-640
Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular pathobiology of pulmonary hypertension. J Am Coll Cardiol.
2004, 43: 13S-24S
Isoda K, Nishikawa K, Kamezawa Y, Yoshida M, Kusuhara M, Moroi M, Tada N, Ohsuzu F. Osteopontin plays an important role in the development of medial thickening and neointimal formation. Circ Res. 2002, 91: 77-82 Jones JE, Mendes L, Rudd MA, Russo G, Loscalzo J, Zhang YY. Serial noninvasive assessment of progressive pulmonary hypertension in a rat model. Am J Physiol – Heart Circ Physiol. 2002, 283: H364-H371
Kandasamy AD, Chow AK, Ali MAM, Schulz R. Matrix metalloproteinase-2 and myocardial oxidative stress injury:
beyond the matrix. Cardiovasc Res. 2010, 85: 413-423
Kasahara Y, Kiyatake K, Tatsumi K, Sugito K, Kakusaka I. Bioactivation of monocrotaline by P-450 3A in rat liver.
J Cardiovasc Pharm. 1997, 30: 124-129
Keogh A, Benza RL, Corris P, Dartevelle P, Frost A, Kim NH, Lang IM, Pepke-Zaba J, Sandoval J, Mayer E.
Interventional and surgical modalities of treatment in pulmonary arterial hypertension. J Am Coll Cardiol. 2009, 54:
S67–S77
Kögler H, Hartmann O; Leineweber K, Nguyen van P, Schott P, Brodde OE, Hasenfuss G. Mechanical load-dependent regulation of gene expression in monocrotaline-induced right ventricular hypertrophy in the rat. Circ Res. 2003, 93: 230-237
Kodama K, Adachi H. Improvement of mortality by long-term E4010 treatment in monocrotaline-induced pulmonary hypertensive rats. J Pharmacol Exp Ther. 1999, 290: 748-752
Kovacs G, Berghold A, Scheidl S, Olschewski. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J. 2009, 34: 888-894
Krenz M, Robbins J. Impact of beta-myosin heavy chain expression on cardiac function during stress. J Am Coll Cardiol. 2004, 44: 2390-2397
Kurozumi T, Tanaka K, Kido M, Shoyama Y. Monocrotaline-induced renal lesions. Exp Mol Pathol. 1983, 39: 377-386
Kuwahara K, Wang Y, McAnally J, Richardson JA, Bassel-Duby R, Hill JA, Olson EN. TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. J Clin Invest. 2006, 116: 3114-3126
Laudi S, Trump S, Schmitz V, West J, McMurtry IF, Mutlak H, Christians U, Weimann J, Kaisers U, Steudel W.
Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin. Am J Physiol - Lung Cell Mol Physiol. 2007, 293: L630-L638
Lee KW, Jeong JY, Lim BJ, Chang YK, Lee SJ, Na KR, Shin YT, Choi DE. Sildenafil attenuates renal injury in an experimental model of rat cisplatin–induced nephrotoxicity. Toxicology. 2009, 257: 137-143
Leeuwenburgh BPJ, Helbing WA, Steendijk P, Schoof PH, Baan J. Biventricular systolic function in young lambs subject to chronic systemic right ventricular pressure overload. Am J Physiol – Heart Circ Physiol. 2001, 281:
H2697-H2740
Leineweber K, Brandt K, Wludyka B, Beilfuß A, Pönicke K, Heinroth-Hoffmann I, Brodde OE. Ventricular hypertrophy plus neurohumoral activation is necessary to alter the cardiac β-adrenoceptor system in experimental heart failure. Circ Res. 2002, 91: 1056-1062
LekanneDeprez RH, van der Hoff MJB, de Boer PAJ, Ruijter JM, Maas AAW, Chamuleau RAFM, Lamers WH, Moorman AFM. Changing patterns of gene expression in the pulmonary trunk-banded rat heart. J Mol Cell Cardiol.
1998, 30: 1877-1888
Lepetit H, Eddahibi S, Frisdal E, Munaut C, Noel A, Humbert M, Adnot S, D’Ortho MP, Lafuma C. Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur Respir J. 2005, 25: 834-842 Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BLM. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest. 1998, 101: 1468-1478
Livak KJ, Flood SJ, Marmaro J, Giusti W, Deetz K. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl. 1995, 4:357-362.
Lock EA. Sensitive and early markers of renal injury: where are we and what is the way forward? Toxicol Sci.
2010, 116: 1-4
Lorenzen JM, Nickel N, Krämer R, Golpon H, Westerkamp V, Olsson KM, Haller H, Hoeper MM. Osteopontin in patients with idiopathic pulmonary hypertension. Chest. 2010, 139: 1010-1017
Lourenço AP, Roncon-Albuquerque R, Brás-Silva C, Faria B, Wieland J, Henriques-Coelho T, Correia-Pinto J, Leite-Moreira AF. Myocardial dysfunction and neurohumoral activation without remodeling in left ventricle of monocrotaline-induced pulmonary hypertensive rats. Am J Physiol – Heart Circ Physiol. 2006, 291: H1587-H1594 Marin-Grez M, Fleming JT, Steinhausen M. Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature. 1986, 324: 473-476
Marsboom GR, Janssens SP. Models for pulmonary hypertension. Drug Discov Today. 2004, 1: 289-296
Matsusaka H, Ide T, Matsushima S, Ikeuchi M, Kubota T, Sunagawa K, Kinugawa S, Tsutsui H. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload.
Hypertension. 2006, 47: 711-717
Meyrick B, Gamble W, Reid L. Development of crotalaria pulmonary hypertension: hemodynamic and structural study. Am J Physiol – Heart Circ Physiol. 1980, 239: H692-H702
Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM; Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005, 365: 1231-1238
Mishra J, Ma Q, Prada A. Mitsnefes MM, Zahedi K, Yang J, Barasch J, Devarajan P. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. Am J Nephrol. 2003, 14: 2534-2543
Miyata S, Minobe W, Bristow MR, Leinwand A. Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ Res. 2000, 86: 386-390
Morioka S, Honda M, Ishikawa S, Ishinaga Y, Yano S, Tanaka K, Moriyama K. Changes in contractile and non-contractile proteins, intracellular Ca2+ and ultrastructures during the development of right ventricular hypertrophy and failure in rats. Jap Circ J. 1992, 56: 469-474
Mukherjee D, Sen S. Collagen phenotypes during development and regression of myocardial hypertrophy in spontaneously hypertensive rats. Circ Res. 1990, 67: 1474-1480
Mukherjee R, Brinsa TA, Dowdy KB, Scott AA, Baskin JM, Deschamps AM, Lowry AS, Escobar GP, Lucas DG, Yarbrough WM, Zile MR, Spinale FG. Myocardial infarct expansion and matrix metalloproteinase inhibition.
Circulation. 2003, 107: 618-625
Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, Shirakami G, Jougasaki M, Obata K, Yasue H, Kambayashi Y, Inouye K, Imura H. Brain natriuretic peptide as a novel cardiac hormone in humans. J Clin Invest.
1991, 87: 1402-1412
Murray F, MacLean MR, Pyne NJ. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol. 2002, 137: 1187-1194
Nagai R, Zarain-Herzberg A, Brandl J, Fujii J, Tada M, MacLennan DH, Alpert N, Periasamy M. Regulation of myocardial Ca2+-ATPase and phospholamban mRNA expression in response to pressure overload and thyroid hormone. Proc Natl Acad Sci USA. 1989, 86: 2966-2970
Nagaya N, Nishikimi T, Okano Y, Uematsu M, Satoh T, Kyotani S, Kuribayashi S, Hamada S, Kakishita M, Nakanishi N, Takamiya M, Kunieda T, Matsuo H, Kangawa K. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol. 1998, 31:
202-208
Nagaya N, Nishikimi T, Uematsu M, Satoh T, Satoh T, Kyotani S, Sakamaki F, Kakishita M, Fukushima K, Okano Y, Nakanishi N, Miyatake K, Kangawa K. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000, 102: 865-870
Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system. II:
Natriuretic peptide receptors. J Hypertens. 1992, 10: 1111-1114
Nakayama H, Wilkin BJ, Bodi I, Molkentin JD. Calcineurin-dependent cardiomyopathy is activated by TRPC in the adult mouse heart. FASEB J. 2006, 20: 1660-1670
Niizuma S, Iwanaga Y, Yahata T, Tamaki Y, Goto Y, Nakahama H, Miyazaki S. Impact of left ventricular diastolic wall stress on plasma B-type natriuretic peptide in heart failure with chronic kidney disease and end-stage renal disease. Clin Chem. 2009, 55: 1347-1353
Nishida M, Kurose H. Roles of TRP channels in the development of cardiac hypertrophy. Naun-Schmiedeberg`s
Nishida M, Onohara N, Sato Y, Suda R, Ogushi M, Tanabe S, Inoue R, Mori Y, Kurose H. Gα12/13-mediated up-regulation of TRPC-6 negatively regulates endothelin-1-induced cardiac myofibroblast formation and collagen synthesis through nuclear factor of activated T cells activation. J Biol Chem. 2007, 282: 23117-23128
Olschewski H, Seeger W, Grimminger F. Physiologie und Pathophysiologie der pulmonalen Zirkulation. Internist.
1999, 40: 696-709
Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Sitbon O, Speich R, Hoeper M, Behr J, Winkler J, Seeger W, for the AIR Study Group. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med. 2002, 347: 322–329
Olschewski H, Ghofrani HA, Enke B; Reichenberger F, Voswinckel R, Kreckel A, Ghofrani S, Wiedemann R, Schulz R, Grimminger F, Seer W. Medikamentöse Therapie der pulmonalen Hypertonie. Internist. 2005, 46: 341-349:
O`Regan A. The role of osteopontin in lung disease. Cyt Growth Fac Rev. 2003, 14: 479-488
Palmer BM. Thick filament proteins and performance in human heart failure. Heart Fail Rev. 2005, 10: 187-197 Peterson JT, Hallak H, Johnson L, Li H, O’Brien P, Sliskovic DR, Bocan TMA, Coker ML, Etoh T, Spinale FG.
Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation. 2001, 103: 2303-2309
Pichler RH, Franceschini N, Young BA, Hugo C, Andoh TF, Burdmann EA, Shankland SJ, Alpers CE, Bennett WM, Couser WG, Johnson RJ. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin.
J Am Soc Nephrol. 1995, 6: 1186-1196
Plestina R, Stoner HB. Pulmonary edema in rats given monocrotaline pyrrole. J Pathol. 1972, 106: 235-249 Polyakova V, Hein S, Kostin S, Ziegelhoeffer T, Schaper J. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coll Cardiol. 2004, 44: 1609-1618
Rademaker MT, Charles CJ, Kosoglou T, Protter AA, Espiner EA, Nicholls MG, Richards AM. Clearance receptors and endopeptidase: equal role in natriuretic peptide metabolism in heart failure. Am J Physiol – Heart Circ Physiol. 1997, 273: H2372-H2379
Reid MR. Partial occlusion of the pulmonary aorta and inferior vena cava with the metallic band. Observations on changes in the vessel wall and in the heart. J Exp Med. 1924, 40: 289-291
Reindel JF, Ganey PE, Wagner JG, Slocombe RF, Roth RA. Development of morphologic, hemodynamic, and biochemical changes in lungs of rats given monocrotaline pyrrole. Toxicol Appl Pharmacol. 1990, 106: 179-200 Rodríguez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Espinoza F, Pons H, Vaziri ND. Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage. Kidney Int. 2005, 68: 2131-2142 Rosenberg HC, Rabinovitch M. Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am J Physiol – Heart Circ Physiol. 1988, 255: H1484-H1491
Rosenkranz S. Pulmonary hypertension: current diagnosis and treatment. Clin Res Cardiol. 2007, 96: 527-541
Roth RA, Dotzlaf LA, Baranyl B, Kuo CH, Hook JB. Effect of monocrotaline ingestion on liver, kidney, and lungs of rats. Toxicol Appl Pharmacol. 1981, 60: 193-203
Schäfer S, Ellinghaus P, Janssen W, Kramer F, Lustig K, Milting H, Kast R, Klein M. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodeling. Cardiovasc Res.
2009, 82: 30-39
Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous, Ermert L, Ermert M, Weissmann N, Rose F, Guenther A, Walmrath, Seeger W, Grimminger F. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med. 2004, 169: 39-45
Schermuly RT, Stasch JP, Pullamsetti SS, Middendorff R, Müller D, Schlüter KD, Dingendorf A, Hackemack S, Kolosionek E, Kaulen C, Dumitrascu R, Weissmann N, Mittendorf J, Klepetko W, Seeger W, Ghofrani HA, Grimminger F. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J. 2008, 32: 881-891
Schoental R, Head MA. Pathological changes in rats as a result of treatment with monocrotaline. Br J Cancer.
1955, 9: 229-237
Schultze AE, Roth RA. Chronic pulmonary hypertension – the monocrotaline model and involvement of the hemostatic system. J Toxicol Environ Health B Crit Rev . 1998, Part B, 1: 271-346
Schultze AE, Wagner JG, White SM, Roth RA. Early indications of monocrotaline pyrrole-induced lung injury in rats. Toxicol Appl Pharmacol. 1991, 109: 41-50
Sekarski N, Fridez P, Corno AF, Segesser von LK, Meijboom EJ. Doppler-guided regulation of a telemetrically operated adjustable pulmonary banding system. J Am Coll Cardiol. 2004, 44: 1087-1094
Seth M, Sumbilla C, Mullen SP, Lewis D, Klein MG, Hussain A, Soboloff J, Gill DL, Inesi G. Sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA) gene silencing and remodeling of the Ca2+ signaling mechanism in cardiac myocytes. Proc Natl Acad Sci USA. 2004, 101: 16683-16688
Seyfarth T, Gerbershagen HP, Giessler C, Leineweber K, Heinroth-Hoffmann I, Pönicke K, Brodde OE. The cardiac β-adrenoceptor–G–protein(s)–adenylyl cyclase system in monocrotaline-treated rats. J Mol Cell Cardiol.
2000, 32: 2315-2326
Seymour AA, Norman JA, Asaad MM, Fennell SA, Abboa-Offei B, Little DK, Kratunis VJ, Delaney NG; Hunt JT, Di Donato G. Possible regulation of atrial natriuretic factor by neutral endopeptidase 24.11 and clearance receptors.
J Pharmacol Exp Ther. 1990, 256: 1002-1008
Singh K, Sirokman G, Communal C, Robinson KG, Conrad CH, Brooks WW, Bing OHL, Colucci WS. Myocardial osteopontin expression coincides with heart failure. Hypertension. 1999, 33: 663-670
Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Herve P, Simonneau G.
Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005, 111: 3105–3111.
Spinale FG. Matrix metalloproteinase: regulation and dysregulation in the failing heart. Circ Res. 2002, 90: 520-530
Stasch JP, Hirth-Dietrich C, Ganten D, Wegner M. Renal and antihypertensive effects of neutral endopeptidase inhibition in transgenic rats with an extra renin gene. Am J Hypertens. 1996, 9: 795-802
Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiß U, Schröder H, Schroeder W, Stahl E, Steinke W, Straub A, Schramm M. NO-independent regulatory site on soluble guanylate cyclase. Nature. 2001, 410: 212-215
Stasch JP, Dembowsky K, Perzborn E, Stahl E, Schramm M. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br J Pharmacol. 2002, 135:344-355.
Stasch JP, Hobbs AJ. NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol. 2009, 191: 277-308
Szalay G, Sauter M, Haberland M, Zuegel U, Steinmeyer A, Kandolf R, Klingel K. Osteopontin: a fibrosis-related marker molecule in cardiac remodeling of enterovirus myocarditis in the susceptible host. Circ Res. 2009, 104:
851-859
Taichmann DB, Mandel J. Epidemiology of Pulmonary Arterial Hypertension. Clin Chest Med. 2007, 28: 1-22 Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, Voelkel NF, Tuder RM.
Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 2001, 15: 427-438
Tozzi R, Palladini G, Fallarini S, Nano R, Gatti C, Presotto C, Schiavone A, Micheletti R, Ferrari P, Fogari R, Perlini S. Matrix metalloprotease activity is enhanced in the compensated but not in the decompensated phase of pressure overload hypertrophy. Heart. 2007, 20: 663-669
Tulevski II, Groenink M, van der Wall EE, van Velduisen DJ, Boomsma F, Stoker J, Hirsch A, Lemkes JS, Mulder BJM. Increased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure overload:
correlation between plasma neurohormones and right ventricular dysfunction. Heart. 2001, 86: 27-30
Umar S, Hessel M, Steendijk P, Bax W, Schutte C, Schalij M, van der Wall E, Atsma D, van der Laarse A.
Activation of signaling molecules and matrix metalloproteinases in right ventricular myocardium of rats with pulmonary hypertension. Pathol Res Pract. 2007, 203: 863-872
Vaidya VS, Ozer JS, Dieterle F, Collings FB, Ramirez V, Troth S, Muniappa N, Thudium D, Gerhold D, Holder DJ, Bobadilla NA, Marrer E, Perentes E, Cordier A, Vonderscher J, Maurer G, Goering PL, Sistare FD, Bonventre JV.
Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotech. 2009, 28: 478-485
Versluis JP, Heslinga JW, Sipkema P, Westerhof N. Contractile reserve but not tension is reduced in monocrotaline-induced right ventricular hypertrophy. Am J Physiol – Heart Circ Physiol. 2004, 286: H979-H984 Viellard-Baron A, Frisdal E, Raffestin B, Baker AH, Eddahibi S, Adnot S, D’Ortho MP. Inhibition of matrix metalloproteinase by lung TIMP-1 gene transfer limits monocrotaline-induced pulmonary vascular remodeling in rats. Hum Gene Ther. 2003, 14: 861-869
Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, Dupius J, Long CS, Rubin LJ, Smart FW, Suzuki YJ, Gladwin M, Denholm EM, Gail DB. Right ventricular function and failure: report of a national heart, lung and blood institute working group on cellular and molecular mechanisms of right heart failure. Circulation.
2006; 114: 1883-1891